{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:03:47Z","timestamp":1771567427203,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>OnabotulinumtoxinA treatment for glabellar lines (GL) or crow's-feet lines (CFL) was previously studied in Japanese subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To assess safety and efficacy of repeated onabotulinumtoxinA for moderate to severe GL and CFL in Japanese subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>This 13-month, double-blind, Phase 3 study randomized subjects to onabotulinumtoxinA 44 U (<jats:italic toggle=\"yes\">n<\/jats:italic> = 48) or 32 U (<jats:italic toggle=\"yes\">n<\/jats:italic> = 53) for CFL and GL for up to 5 treatments (CFL: 24 U or 12 U; GL: 20 U). Outcomes included proportion of subjects achieving none\/mild severity at maximum smile (CFL) and maximum frown (GL), using the Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A); proportion of \u22651-grade improvement responders at maximum smile and at rest (CFL), at maximum frown and at rest (GL); subject-reported outcomes; and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Most subjects were responders (none\/mild on FWS-A; CFL: 89.6% [44 U], 84.9% [32 U]; GL: 93.8% [44 U], 98.1% [32 U]) on Day 30. Across treatment groups, responder rates were consistent over time and treatments. Most subjects were satisfied with improved CFL appearance and with treatment. Incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs across groups was similar. All TEAEs but one (peritonitis) were mild or moderate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Repeated onabotulinumtoxinA was effective and well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002143","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T02:12:10Z","timestamp":1568340730000},"page":"483-490","source":"Crossref","is-referenced-by-count":9,"title":["Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects"],"prefix":"10.1097","volume":"46","author":[{"given":"Makoto","family":"Kawashima","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonori","family":"Harii","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Kyorin University School of Medicine, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Akihabara Skin Clinic, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Seidman","sequence":"additional","affiliation":[{"name":"Peloton Advantage, LLC, Parsippany, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Lei","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Hopfinger","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Lee","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaad.2009.01.005","article-title":"A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy","volume":"60","author":"Carruthers","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crow's feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2009.06.040","article-title":"Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants","volume":"61","author":"Brin","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol Surg"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1467-2494.2006.00302.x","article-title":"Ethnic skin types: are there differences in skin structure and function?","volume":"28","author":"Rawlings","year":"2006","journal-title":"Int J Cosmet Sci"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/derm.22372","article-title":"Genetics and skin aging","volume":"4","author":"Makrantonaki","year":"2012","journal-title":"Dermatoendocrinol"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00266-017-0844-9","article-title":"OnabotulinumtoxinA (Botox) in the treatment of crow's feet lines in Japanese subjects","volume":"41","author":"Harii","year":"2017","journal-title":"Aesthet Plast Surg"},{"key":"R9-20230814","first-page":"1084","article-title":"Efficacy and safety of incobotulinumtoxinA in Asian subjects: a pooled analysis of clinical trials in the treatment of glabellar frown lines","volume":"15","author":"Seo","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04071.x","article-title":"An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects","volume":"48","author":"Kawashima","year":"2009","journal-title":"Int J Dermatol"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1524-4725.2006.32326.x","article-title":"Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes","volume":"33","author":"Carruthers","year":"2007","journal-title":"Dermatol Surg"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:43:34Z","timestamp":1692042214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002143","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}